FindTrial
Sign In

Therapeutic effect of small-dose and medium dose intravitreal ganciclovir for AIDS patients with cytomegalovirus retinitis

Therapeutic effect of small-dose and medium dose intravitreal ganciclovir for AIDS patients with cytomegalovirus retinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053927
Enrollment
Unknown
Registered
2021-12-02
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cytomegalovirus retinitis

Interventions

Experimental group1:Intravitreal 0.4 mg/0.1 mL ganciclovir
Experimental group2:Intravitreal 2 mg/0.1 mL ganciclovir

Sponsors

Nanning Aier Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: AIDS patients were complicated with CMVR and aged > 18 years.

Exclusion criteria

Exclusion criteria: Patients who had been treated for CMVR before or CMVR complicated with retinal detachment.

Design outcomes

Primary

MeasureTime frame
best corrected visual acuity;Injection number;complication;—

Countries

China

Contacts

Public ContactLiang Xuemei

Nanning Aier Eye Hospital

lxmyanke@163.com+86 13768300459

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026